Clinical trial · Interventional
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CNS Germ Cell Tumor | Central Nervous System Germ Cell Tumor | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx). | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
- description
- Two to four cycles of induction therapy with open label GemPOx followed by consolidation and autologous stem cell transplant (ASCT).
- interventionNames
- Drug: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Primary outcomes (2)
- measure
- Response Rate
- timeFrame
- 16-32 weeks depending on individual patient response (remaining disease burden) to chemotherapy
- description
- To estimate response rate after at least two and up to four courses of induction chemotherapy with GemPOx regimen in patients with recurrent intracranial MMGCT
- measure
- The Rate of Completion of Induction Chemotherapy and Progression to High-dose Chemotherapy (HDC) With Autologous Hematopoietic Progenitor Cell Rescue (AuHPCR)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * ICGCT including pure germinoma and MMGCT. * Patients with histologically proven germinoma and MMGCT, including endodermal sinus tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor will be eligible for the study. * Patients with mature/immature teratoma who have tumor marker elevations are eligible on this study. * Patient with ONLY mature and/or immature teratoma are ineligible in the absence of the tumor marker elevations. Exclusion Criteria: * Patients with ICGCTs who are newly diagnosed are excluded from the study. * Patients with the diagnosis of mature or immature teratoma in the absence of tumor marker elevations are excluded from the study. * Patients who are pregnant or breastfeeding are excluded from the study. * Patients who have received previously a high dose chemotherapy regimen and autologous transplant are excluded from this study. * Patients who have received gemcitabine, oxaliplatin and/or paclitaxel are excluded from this study.
References
Publications (0)
Data not yet available